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Purpose: This study aims to examine the differences in characteristics, treatment and survival 
between Asian and European women diagnosed in stage I-III breast cancer in New Zealand. 
Methods: The studied population included European women and Asian women diagnosed with 
stage I-III breast cancer between June 2000 and May 2013 identified from the combined Waikato 
and Auckland Breast Cancer Registers. Characteristics and treatment were compared between 
Asian and European women. Kaplan-Meier method was used to examine the survival difference. 
Cox proportional hazards model was used to estimate the hazard ratio (HR) of mortality. 
Results: The studied cohort included 8608 European and 949 Asian women. Asian women were 
younger, had less comorbidities and were less likely to be obese than European women. Asian 
women were more likely to have grade 3, larger and HER2+ breast cancers. Asian women were 
more likely to receive mastectomy, less likely to have reconstruction after mastectomy, less likely 
to have chemotherapy, and less likely to be treated with trastuzumab if HER2+ and had better 
adherence to endocrine therapy (adjusted odds ratio: 1.54; 95% CI: 1.22-1.93). Asian women had 
better cancer-specific and all-cause survival than European women. The adjusted HR of cancer-
specific mortality and all-cause mortality was 0.64 (95% CI: 0.49-0.82) and 0.68 (95% CI: 0.55-
0.84).  
Conclusions: Asian women are more likely to have high grade, larger and HER2+ breast cancers 
than European women. In spite of this, they had better breast cancer outcomes. Possible 












Breast cancer is the most frequently diagnosed cancer in women, impacting 2.1 million women 
each year around the world in 2018, and is also the commonest cause of cancer death for 
women.[1, 2] Diversity in cancer characteristics, treatment and survival between different ethnic 
groups has been well documented.[3-9] Compared to European, Hispanic and Asian women in the 
US, African American women have the highest risk of having triple negative breast cancer that is 
associated with a poor outcome.[4] Japanese and Filipino women were found to be less likely to 
receive breast conserving surgery than white women.[3] Asian women are more likely to have 
human epidermal growth factor receptor 2 positive (HER2+) than European (10.9% vs 7.0%).[4] 
African American women have worse breast cancer-specific survival and Asian women have better 
survival than European women.[4, 5] 
European, Māori, Pacific and Asian are the four main ethnic groups in New Zealand. It has been 
demonstrated that Māori and Pacific women were more likely to be diagnosed with advanced 
breast cancer, have disadvantages in access to treatment and have poorer survival compared to 
European women.[6-15] Breast cancer in Asian women has rarely been studied in New Zealand, 
but the above studies suggested that Asian women in New Zealand may have better outcomes 
that the other groups.  
In New Zealand, Asian ethnicity account for 11.8% (471,708) of the population  in 2013, increasing 
from 9.2% (354,552) in 2006.[16] The Asian ethnic group is getting older, with a median age of 
28.6 years in 2006 and a median age of 30.6 years in 2013.[16] The health needs of Asian are 
changing with the increasing population and the aging problem. This study aims to examine the 
differences in characteristics, treatment and survival between Asian and European women 
diagnosed in stage I-III breast cancer in New Zealand.  
 
Methods 
The studied population included European women and Asian women diagnosed with stage I-III 
breast cancer between June 2000 and May 2013 identified from the combined Waikato and 
Auckland Breast Cancer Registers.[17] The registers’ data includes: 1) patient characteristics: age, 
ethnicity and BMI (body mass index); 2) tumour information: diagnosis date, cancer stage, cancer 
grade, tumour size and biomarkers including estrogen receptor (ER), progesterone receptor (PR), 
human epidermal growth factor receptor 2 (HER2), and 3) information on treatment: surgery 
(including breast conserving surgery (BCS) and mastectomy), chemotherapy, trastuzumab, 
endocrine therapy and radiation therapy. Ethnicity was self-identified as part of the registers 
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consent process. The classification of New Zealand European women and Asian women followed 
the Ethnicity New Zealand Standard Classification (2005 V2.0.0).[18] 
Information on comorbidities has been obtained by reviewing linked data from the National 
Minimum dataset (NMDS) by National Health Index number (NHI) and categorising patients using 
the C3 comorbidity index: [19, 20] 1) less or equal to zero, 2) greater than zero but less or equal 
to one, and 3) greater than one. BMI were grouped into <18.5 (underweight), 18.5~25 (normal), 
25~30 (overweight) and ≥30 (obese). In this study, HER2+ was defined as FISH amplified or IHC 
3+ according to the 2013 American Society of Clinical Oncology (ASCO) guideline.[21] 
Recommended in the 2001 St. Gallen Consensus, ER+ or PR+ was assessed as IHC positive 
(1+).[22] Based on the status of the three biomarkers ER, PR and HER2, five cancer subtype 
groups were categorised including Luminal A, Luminal B HER2-, Luminal B HER2+, HER2+ non-
luminal and triple negative.[9, 23] Patient and tumour characteristics were compared between 
Asian and European women. Chi-square test was used to examine the differences between the 
two ethnic groups.  
The PHARMS dataset contains claim and payment information from pharmacists for subsidised 
dispensings. Adherence to endocrine therapy was investigated in patients diagnosed in 2005-13, 
because 2005 was the first year that over 80% of pharmaceutical dispensing records reported NHI 
in the PHARMS dataset. The quality of PHARMS data has improved and in 2010 NHI was provided 
for approximately 97% of pharmaceutical dispensing.[24] An adherence index/medication 
possession ratio (MPR) for each woman was calculated by dividing the number of days covered 
by endocrine therapy with the number of days for up to 5 years unless censored by death or the 
conclusion of the study (31 December 2014). A MPR of 80% or more was considered to be 
high/optimal level of adherence.[25-27] Stepwise logistic regression model was used to estimate 
the odds ratio of treatment and adherence to endocrine therapy between the two groups. 
Patient outcomes include breast cancer-specific survival and all-cause survival. These mortality 
data were derived from the New Zealand National Mortality Collection. For all-cause survival 
analyses, patients without a documented record of death were considered to be censored on the 
last updated date for Mortality Collection which was 31 December 2014. For cancer-specific 
analyses, deaths from other causes were censored on the date of death. Kaplan-Meier method 
was used to examine the survival between Asian and European women, as well as the survival 
between Asian subgroups (Chinese, Southeast Asian, Indian and other Asian). We used Cox 
proportional hazards model to estimate the hazard ratio (HR) of breast cancer-specific mortality 
and all-cause mortality between Asian and European women after adjustment for characteristics 






The studied cohort included 8608 European women and 949 Asian women (317 Chinese, 225 
Indian, 94 Southeast Asian and 313 other Asian). The number of Asian women diagnosed with 
stage I-III breast cancer has been increasing rapidly, from 148 in 2000-03 to 331 in 2010-13 (Table 
1). Asian women who were diagnosed with stage I-III breast cancer were generally younger 
(average age: 53 years vs 60 years) and had less comorbidities than European women. Compared 
to 78.7% of European women, 86.7% of Asian women had no severe comorbidities. BMI data was 
only available in 28.0% of patients. Among those with BMI information, 30.2% of European were 
obese (BMI≥30) compared to 15.4% of Asian women. A higher proportion of Asian women were 
diagnosed with grade 3 breast cancer than European women (36.6% vs 27.3%), as well as HER2+ 
breast cancer (16.0% vs 11.8%). The tumour size for Asian women was larger than that for 
European women. 
Asian women were more likely to receive mastectomy rather than BCS compared to European 
women (Table 2). The odds ratio of Asian women having BCS compared to European was 0.63 
(95% confidence interval (CI): 0.54-0.74) after adjustment for age, year, register, screen detection, 
public/private treatment, cancer stage, grade, tumour size and subtype. Among the 532 Asian 
women diagnosed with T1 breast cancer, 41.0% (218) had mastectomy and 59.0% (314) had BCS. 
The respective percentage was 28.5% and 70.7% for European women diagnosed with T1 breast 
cancer.  Asian women were also less likely to have reconstruction after mastectomy (adjusted 
odds ratio: 0.34), less likely to have chemotherapy (adjusted odds ratio: 0.73), and less likely to be 
treated with trastuzumab if tested HER2+ (adjusted odds ratio: 0.43). Use of radiotherapy and 
endocrine therapy for ER/PR positive cancer were similar between the two ethnic groups. Asian 
women had better adherence to endocrine therapy with an adjusted odds ratio of 1.54 (95% CI: 
1.22-1.93, p-value<0.001). 
Asian women had better breast-cancer specific survival and all-cause survival than European 
women (Figure 1 and 2). The crude HR of breast-cancer mortality for Asian women compared to 
European women was 0.60 (95% CI: 0.47-0.78), and the crude HR of all-cause mortality was 0.66 
(95% CI: 0.53-0.81). The respective HR was 0.64 (95% CI: 0.49-0.82) and 0.68 (95% CI: 0.55-
0.84) after adjustment for characteristics and treatments (Table 3). Better breast cancer-specific 
survival and all-cause survival were associated with fewer comorbidities, younger age, diagnosed 
in recent years, earlier cancer stage, lower cancer grade, smaller tumour size, less aggressive 
subtypes, having surgery, chemotherapy, radiotherapy and good adherence to endocrine therapy. 
The Kaplan-Meier method showed that Chinese, Indian and other Asian women had similar breast 
cancer-specific survival, but Southeast Asian women had worse survival than other Asian 
subgroups (Figure 3. log-rank test p-value =0.016). The adjusted hazard ratio of breast cancer-






This study shows that Asian women with stage I-III breast cancer have better survival than 
European women. This is consistent with two American studies [4, 5] demonstrating a lower HR of 
mortality in Asian women compared to European women. However, in these two studies, the Asian 
group includes Pacific islanders who were found to have the worst survival of breast cancer 
compared to other ethnic groups in New Zealand.[28, 29] If Pacific women were not included in 
the Asian group, the HR of death in Asian women would likely have been even lower. Among the 
Asian subgroups, Southeast Asian women had the worst survival, as found in another American 
study compared to Chinese and Japanese.[30] However, the numbers of Asian subgroups were 
small, therefore the Asian subgroup findings were prone to great uncertainty. The definition of 
Southeast Asian [30-32] was different in other studies, and therefore the comparison with other 
studies is difficult. In New Zealand, Southeast Asian includes Filipino, Cambodian, Vietnamese, 
Indonesian, etc,[18] but Filipino and Vietnamese were not included in the Southeast Asian group 
in some American studies.[32]  
Ten percent of Asian women diagnosed with breast cancer were 70 years or older compared to 
24.6% of European women. This is a reflection in the make-up of the Asian and European 
populations in New Zealand. Five percent of Asian women in New Zealand are 70 years or older 
compared to 14% of European women.[33] 
Asian women have shown better survival from breast cancer, in spite of the fact that they are more 
likely to be diagnosed with HER2+ breast cancer – a factor that is associated with worse 
outcomes.[11] Sixteen percent of Asian women had HER2+ breast cancer compared to 11.8% of 
European women. This has also been found in other studies, but the proportions of HER2+ breast 
cancers were slightly different.[4, 32, 34] The reported percentages of HER2+ breast cancer 
ranged from 20.6% to 36% for Asian women and 16.8% to 19% for European women.[4, 32, 34] 
The better breast cancer outcome in Asian women was partly due to the better adherence to 
endocrine therapy (odds ratio: 1.54). In the Cox proportional hazards model, high adherence to 
endocrine therapy was associated with a decreased risk of breast cancer-specific mortality and all-
cause mortality (respective hazard ratio: 0.41, 0.57). Previous studies have also shown that sub-
optimal adherence to adjuvant endocrine therapy increased the risk of breast cancer recurrence 
and mortality.[27, 35, 36]  
Fewer comorbidities and younger age have a significant impact on both breast cancer-specific and 
all cause survival. Compared to European women, Asian women were younger and were less 
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likely to have comorbidities.[37, 38] Comorbidities in patients with breast cancer can lead to dose 
reduction in chemotherapy and radiotherapy,[37, 38] and consistent underdosing of chemotherapy, 
and dose reductions in radiation therapy limit treatment efficacy and disease outcome.[37-39]  
In Seneviratne’s paper,[15] the survival difference between Māori women and European 
diagnosed with breast cancer disappeared after adjustment for patient characteristics and 
treatment, but the HR in our study did not change substantially after adjustment. That means there 
are some unknown factors contributing to the survival difference between Asian and European 
women. The breast cancer outcome in Asian women may be also associated with their health 
status and life style. The available BMI data show that Asian women were half as likely to be obese 
compared to European women (15.4% vs 30.2%). This is consistent with the data reported in the 
New Zealand Health Survey 2017/18: 15.1% of Asian and 30.7% of New Zealand European were 
obese.[40] Obesity is associated with a higher risk of developing breast cancer, especially in 
postmenopausal women, and with worse disease outcome for women of all ages.[38] Exercise 
and weight loss can reduce breast cancer risk and improve outcomes.[38]  
The New Zealand Health Survey 2017/18 also showed that only 6.5% of Asian people are 
hazardous drinkers but 21.2% of European are hazardous drinkers. Alcohol consumption has an 
adverse impact on survival for women with breast cancer. Drinking ≥ 6 g/d of alcohol compared 
with no drinking after a breast cancer diagnosis increase risk of breast cancer recurrence (HR, 
1.35; 95% CI, 1.00 to 1.83), especially among postmenopausal (HR, 1.51; 95% CI, 1.05 to 2.19) 
and overweight/obese women (HR, 1.60; 95% CI, 1.08 to 2.38).[41] 
The difference in diet between Asian and European women may have an impact on the incidence 
and outcome of breast cancer. An American study found that low intake of meat/starches and high 
intake of legumes is associated with a reduced risk of breast cancer in Asian Americans.[42] A 
meta-analysis also show that a Mediterranean diet including fresh produce, whole grains, and 
legumes, as well as some healthful fats and fish, can reduce the risk of breast cancer.[43]  
The strength of this study is that it comprises a relatively large population based database with 
comprehensive data on patient characteristics, patient treatment as well as outcomes. One 
weakness is that we do not have good data on BMI, exercise, drinking and diet that may explain 
the survival difference between Asian and New Zealand European women. Therefore, we used 
the New Zealand Health Survey data for discussion of possible explanations. It has been found 
that survival after breast cancer is different between immigrant Asian women and locally born Asian 
women.[44, 45] The Breast Cancer Registers do not record immigrant status and therefore we 
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Asian women are more likely to have high grade, larger and HER2+ breast cancers than New 
Zealand European women. In spite of this, they had better breast cancer outcomes. Possible 
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Table 1. Characteristics of NZ European women and Asian women diagnosed with stage I-III 
breast cancer 
Characteristics NZ European Asian Total P-value (Chi-square test) 
Year of diagnosis              
2000-2003 2191 25.5% 148 15.6% 2339 24.5% <0.001 
2004-2006 1878 21.8% 196 20.7% 2074 21.7%  
2007-2009 2033 23.6% 274 28.9% 2307 24.1%  
2010-2013 2506 29.1% 331 34.9% 2837 29.7%  
Comorbidity C3 score              
≤0 6775 78.7% 823 86.7% 7598 79.5% <0.001 
>0&≤1 680 7.9% 60 6.3% 740 7.7%  
>1&≤2 479 5.6% 28 3.0% 507 5.3%  
>2 674 7.8% 38 4.0% 712 7.5%  
Age              
<40 483 5.6% 90 9.5% 573 6.0% <0.001 
40-49 1655 19.2% 339 35.7% 1994 20.9%  
50-59 2247 26.1% 284 29.9% 2531 26.5%  
60-69 2101 24.4% 141 14.9% 2242 23.5%  
70-79 1183 13.7% 71 7.5% 1254 13.1%  
80+ 939 10.9% 24 2.5% 963 10.1%  
BMI        
<18.5 30 1.2% 4 1.5% 34 1.3% <0.001 
18.5~25 844 34.9% 135 51.9% 979 36.5%  
25~30 816 33.7% 81 31.2% 897 33.5%  
≥30 730 30.2% 40 15.4% 770 28.7%  
Unknown 6188  689  6877   
Mode of detection        
Not screen detected 5113 59.4% 590 62.2% 5703 59.7% 0.098 
Screen detected 3495 40.6% 359 37.8% 3854 40.3%  
Node positivity        
No 4935 61.9% 585 63.7% 5520 62.1% 0.298 
Yes 3038 38.1% 334 36.3% 3372 37.9%  
Unknown 635  30  665   
Cancer stage              
I 4019 46.7% 439 46.3% 4458 46.6% 0.919 
II 3298 38.3% 370 39.0% 3668 38.4%  
III 1291 15.0% 140 14.8% 1431 15.0%  
Grade              
1 2148 26.1% 200 21.7% 2348 25.6% <0.001 
2 3843 46.6% 385 41.8% 4228 46.1%  
3 2253 27.3% 337 36.6% 2590 28.3%  
Unknown 364  27  391   
Tumour size (mm)        
0-10 4979 60.0% 532 56.8% 5511 59.7% 0.044 
>20 2877 34.7% 338 36.1% 3215 34.8%  
>50 445 5.4% 66 7.1% 511 5.5%  
Unknown 307  13  320   
Biomarker subtype        
Luminal A 3819 46.3% 440 47.7% 4259 46.5% <0.001 
Luminal B HER2- 859 10.4% 101 11.0% 960 10.5%  
Luminal B HER2+ 600 7.3% 83 9.0% 683 7.5%  
HER2+ non-Luminal 369 4.5% 65 7.0% 434 4.7%  
Triple Negative 852 10.3% 106 11.5% 958 10.5%  
Unknown 2109   154   2263    





Table 2. Treatment difference between European and Asian women with breast cancer 
Treatment European Asian Adjusted OR 95% CI p-value 
Surgery 
       
BCS 4683 54.4% 417 43.9% 0.63† 0.54-0.74 <0.001 
Mastectomy 3577 41.6% 521 54.9%    
No primary surgery 348 4.0% 11 1.2% 
   
        
        
Reconstruction after 
mastectomy 
       
No 2696 75.4% 437 83.9%    
Yes 881 24.6% 84 16.1% 0.34 0.26-0.44 <0.001 
                
Radiotherapy after BCS 
       
No 777 16.6% 77 18.5%    
Yes 3906 83.4% 340 81.5% 0.81 0.62-1.07 0.140 
                
Chemotherapy 
       
No 5561 64.6% 529 55.7%    
Yes 3047 35.4% 420 44.3% 0.73 0.60-0.89 0.002 
        
Trastuzumab for HER2+ women 
  
   
No 410 42.1% 54 36.5%    
Yes 564 57.9% 94 63.5% 0.43 0.27-0.69 <0.001 
        
Endocrine therapy for ER/PR+ women      
No 1783 25.8% 177 23.9%    
Yes 5152 74.2% 564 76.1% 1.06 0.86-1.31 0.602 
        
Adherence to Endocrine therapy in 2005-13     
Low adherence (MPR<80%) 1275 34.7% 132 30.6%    
High adherence (MPR≥80%) 2114 65.3% 256 69.4% 1.54 1.22-1.93 <0.001 




















Table 3. Hazard ratios of breast cancer-specific mortality and all-cause mortality 
Factors† Breast cancer-specific 
mortality 
All-cause mortality 
 Hazard ratio (95% 
CI) 
p-value Hazard ratio (95% 
CI) 
p-value 
Age (continuous) 1.01 (1.00-1.01) 0.041 1.04 (1.04-1.05) <0.001 
Year at diagnosis (continuous) 0.90 (0.88-0.93) <0.001 0.96 (0.94-0.98) <0.001 
C3 comorbidity score     
≤0 Ref  Ref  
>0 & ≤1 1.21 (0.95-1.54) 0.117 1.30 (1.10-1.53) 0.002 
>1 1.25 (1.02-1.53) 0.035 1.86 (1.65-2.10) <0.001 
Ethnicity     
European Ref  Ref  
Asian 0.64 (0.49-0.82) <0.001 0.68 (0.55-0.84) <0.001 
Cancer stage     
I Ref  Ref  
II 2.25 (1.82-2.77) <0.001 1.47 (1.29-1.68) <0.001 
III 5.57 (4.35-7.12) <0.001 3.31 (2.78-3.95) <0.001 
Grade     
1 Ref  Ref  
2 3.49 (2.44-5.01) <0.001 1.34 (1.15-1.56) <0.001 
3 6.38 (4.42-9.23) <0.001 1.99 (1.68-2.35) <0.001 
Tumour size (mm, continuous) 1.01 (1.01-1.01) <0.001 1.01 (1.01-1.01) <0.001 
Subtype     
Luminal A Ref  Ref  
Luminal B HER2- 2.20 (1.75-2.76) <0.001 1.59 (1.35-1.89) <0.001 
Luminal B HER2+ 1.48 (1.13-1.93) 0.004 1.20 (0.97-1.48) 0.094 
HER2+ non-luminal 2.13 (1.54-2.95) <0.001 1.40 (1.09-1.79) 0.009 
Triple negative 2.53 (1.90-3.35) <0.001 1.65 (1.35-2.01) <0.001 
Surgery     
Breast conserving surgery Ref  Ref  
Mastectomy 1.28 (1.08-1.52) 0.004 1.10 (0.97-1.25) 0.120 
No primary surgery 5.49 (3.11-9.68) <0.001 3.43 (2.47-4.76) <0.001 
Radiotherapy      
No Ref  Ref  
Yes 0.77 (0.65-0.92) 0.003 0.66 (0.58-0.75) <0.001 
Chemotherapy     
No Ref  Ref  
Yes 0.76 (0.63-0.92) 0.005 1.02 (0.88-1.18) 0.784 
Endocrine therapy     
No Ref  Ref  
Yes 1.03 (0.83-1.27) 0.797 0.92 (0.800-1.05) 0.205 
Adherence to endocrine therapy     
Low adherence (MPR<80%) Ref  Ref  
High adherence (MPR≥80%) 0.41 (0.31-0.53) <0.001 0.57 (0.47-0.68) <0.001 
† Trastuzumab was not included in the model because of the small number of patients receiving 
trastuzumab.  
